# P2RY12

## Overview
The P2RY12 gene encodes the purinergic receptor P2Y12, a G-protein-coupled receptor (GPCR) that plays a pivotal role in platelet aggregation and hemostasis. This receptor is primarily expressed in platelets, where it is activated by adenosine diphosphate (ADP), leading to a cascade of intracellular events that promote platelet activation and aggregation (von2017Structure; Gachet2012P2Y12). Structurally, the P2Y12 receptor is characterized by a seven transmembrane domain typical of GPCRs, with unique features that distinguish it from other class A GPCRs, such as a straight conformation of helix V and specific interactions with cholesterol molecules (Zhang2014Structure; Cattaneo2015P2Y12). Beyond its role in platelets, P2Y12 is also expressed in vascular smooth muscle cells and immune cells, where it contributes to vasoconstriction and inflammatory responses, respectively (Wihlborg2004ADP; Entsie2023The). The receptor's involvement in these processes underscores its significance in both cardiovascular and immune system functions, making it a critical target for antithrombotic therapies and a subject of interest in various clinical contexts, including cardiovascular diseases and bone remodeling disorders (Su2012The; Su2023Association).

## Structure
The P2Y12 receptor (P2RY12) is a G-protein-coupled receptor (GPCR) characterized by a canonical seven transmembrane (7TM) domain structure, typical of GPCRs, which facilitates its role in platelet aggregation (Zhang2014Agonistbound; Cattaneo2015P2Y12). The receptor is composed of 342 amino acids and includes two potential N-linked glycosylation sites at its extracellular amino terminus, which may influence its activity (Cattaneo2015P2Y12). 

The secondary structure of P2RY12 includes tilted and/or kinked transmembrane helices, with a carboxy-terminal helix VIII parallel to the membrane lipid bilayer (Cattaneo2015P2Y12). The receptor's tertiary structure reveals a unique straight conformation of helix V, distinguishing it from other class A GPCRs, and lacks the conserved proline and corresponding bend in helix V (Zhang2014Structure). 

The receptor's quaternary structure involves interactions with cholesterol molecules, which may play a role in signal transduction (Cattaneo2015P2Y12). The P2Y12 receptor also features a potentially labile disulfide bond between C97 and C175, which is different from other GPCRs (Zhang2014Structure). These structural features are crucial for its function and interaction with ligands.

## Function
The P2RY12 gene encodes the P2Y12 receptor, a G-protein-coupled receptor primarily expressed in platelets and involved in platelet aggregation, a critical process in hemostasis and thrombosis. The receptor is activated by ADP, leading to the inhibition of adenylyl cyclase, which reduces cyclic AMP (cAMP) levels and promotes platelet activation and aggregation (von2017Structure; Gachet2012P2Y12). This receptor is essential for the stabilization of platelet aggregates and the amplification of responses to other agonists like thrombin and thromboxane A2 (TXA2) (Gachet2012P2Y12; Mansour2020P2Y12).

In addition to its role in platelets, P2Y12 is expressed in other cell types, including vascular smooth muscle cells and immune cells such as monocytes and macrophages. In vascular smooth muscle cells, P2Y12 contributes to vasoconstriction and may play a role in atherogenesis (von2017Structure; Wihlborg2004ADP). In immune cells, P2Y12 influences inflammatory responses and cell migration, particularly in macrophages, where it is linked to migration towards ADP-rich areas (Entsie2023The). The receptor's involvement in these processes highlights its importance in both vascular and immune system functions.

## Clinical Significance
Mutations and polymorphisms in the P2RY12 gene have been associated with various cardiovascular and bleeding disorders. The P2RY12 H2 haplotype is linked to an increased risk of acute myocardial infarction (AMI) and peripheral arterial disease (PAD), as it enhances ADP-induced platelet aggregation, a key factor in arterial thrombosis (Su2023Association; Fontana2003P2Y). In Kawasaki disease, the rs7637803 polymorphism in P2RY12 is associated with an increased risk of coronary artery aneurysm, particularly in children and males (Lu2019P2RY12:rs7637803).

The P2RY12 gene also plays a role in clopidogrel resistance, a condition that affects the efficacy of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Variations at C34T and G52T in the P2RY12 gene significantly increase the risk of clopidogrel resistance and adverse cardiovascular events (Li2017Associations).

In addition to cardiovascular implications, P2RY12 is involved in osteoclast function and bone remodeling. Its deficiency or inhibition can protect against bone loss in conditions like osteoporosis and rheumatoid arthritis, suggesting its role in pathological bone remodeling (Su2012The).

## Interactions
The P2RY12 receptor is a G-protein coupled receptor that primarily interacts with adenosine diphosphate (ADP) to mediate platelet aggregation. It is involved in several signaling pathways, notably through its interaction with Gi/o proteins, which inhibit adenylate cyclase, leading to reduced cAMP levels and subsequent platelet activation (Cornelissen2010Roles). The receptor also forms part of a complex network of interactions with other platelet receptors and proteins, contributing to hemostasis and thrombosis. 

P2RY12 interacts with various ligands, including agonists like 2MeSADP, which bind to specific pockets within the receptor, forming interactions such as π-π interactions with the Y105 side chain and coordination with cationic residues like R256, K280, and Y259 (Zhang2014Agonistbound). The receptor's interaction with antagonists, such as Ticagrelor, is also significant, as these compounds inhibit P2RY12 activity, reducing platelet aggregation and thrombus formation (Chen2022Ginsenoside).

Ginsenoside Rg5 has been shown to allosterically interact with P2RY12, forming a stable complex and antagonizing its activity. This interaction is characterized by a strong binding affinity, similar to that of known antagonists, and involves key amino acid residues such as E188 and R265 (Chen2022Ginsenoside). These interactions highlight the receptor's role in modulating platelet function and its potential as a target for antithrombotic therapies.


## References


[1. (Su2012The) Xinming Su, Desiree H. Floyd, Alun Hughes, Jingyu Xiang, Jochen G. Schneider, Ozge Uluckan, Emanuela Heller, Hongju Deng, Wei Zou, Clarissa S. Craft, Kaiming Wu, Angela C. Hirbe, Dorota Grabowska, Mark C. Eagleton, Sarah Townsley, Lynne Collins, David Piwnica-Worms, Thomas H. Steinberg, Deborah V. Novack, Pamela B. Conley, Michelle A. Hurchla, Michael Rogers, and Katherine N. Weilbaecher. The adp receptor p2ry12 regulates osteoclast function and pathologic bone remodeling. Journal of Clinical Investigation, 122(10):3579–3592, October 2012. URL: http://dx.doi.org/10.1172/jci38576, doi:10.1172/jci38576. This article has 85 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci38576)

[2. (Chen2022Ginsenoside) Ziyu Chen, Gaorui Wang, Xueqing Xie, Heng Liu, Jun Liao, Hailian Shi, Min Chen, Shusheng Lai, Zhengtao Wang, and Xiaojun Wu. Ginsenoside rg5 allosterically interacts with p2ry12 and ameliorates deep venous thrombosis by counteracting neutrophil netosis and inflammatory response. Frontiers in Immunology, August 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.918476, doi:10.3389/fimmu.2022.918476. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.918476)

[3. (Su2023Association) Chunyan Su, Zhishan Zhang, Jintu Chen, Mengcha Tian, Conglian Wu, and Tao Zhang. Association between p2y1 and p2y12 polymorphisms and acute myocardial infarction and adp-induced platelet aggregation. BMC Cardiovascular Disorders, January 2023. URL: http://dx.doi.org/10.1186/s12872-023-03075-4, doi:10.1186/s12872-023-03075-4. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12872-023-03075-4)

[4. (Zhang2014Structure) Kaihua Zhang, Jin Zhang, Zhan-Guo Gao, Dandan Zhang, Lan Zhu, Gye Won Han, Steven M. Moss, Silvia Paoletta, Evgeny Kiselev, Weizhen Lu, Gustavo Fenalti, Wenru Zhang, Christa E. Müller, Huaiyu Yang, Hualiang Jiang, Vadim Cherezov, Vsevolod Katritch, Kenneth A. Jacobson, Raymond C. Stevens, Beili Wu, and Qiang Zhao. Structure of the human p2y12 receptor in complex with an antithrombotic drug. Nature, 509(7498):115–118, March 2014. URL: http://dx.doi.org/10.1038/nature13083, doi:10.1038/nature13083. This article has 316 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature13083)

[5. (Li2017Associations) Miaonan Li, Hongju Wang, Ling Xuan, Xiaojun Shi, Tong Zhou, Ningru Zhang, and Yuli Huang. Associations between p2ry12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after pci in patients with acute coronary syndrome. Medicine, 96(14):e6553, April 2017. URL: http://dx.doi.org/10.1097/md.0000000000006553, doi:10.1097/md.0000000000006553. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/md.0000000000006553)

[6. (Lu2019P2RY12:rs7637803) Zhaoliang Lu, Yufen Xu, Lanyan Fu, Yaqian Tan, Di Che, Ping Huang, Lei Pi, Huazhong Zhou, Xiaoyun Liang, Li Zhang, and Xiaoqiong Gu. P2ry12:rs7637803 tt variant genotype increases coronary artery aneurysm risk in kawasaki disease in a southern chinese population. The Journal of Gene Medicine, January 2019. URL: http://dx.doi.org/10.1002/jgm.3066, doi:10.1002/jgm.3066. This article has 9 citations.](https://doi.org/10.1002/jgm.3066)

[7. (Cornelissen2010Roles) Ivo Cornelissen, Daniel Palmer, Tovo David, Lisa Wilsbacher, Cherry Concengco, Pamela Conley, Anjali Pandey, and Shaun R. Coughlin. Roles and interactions among protease-activated receptors and p2ry12 in hemostasis and thrombosis. Proceedings of the National Academy of Sciences, 107(43):18605–18610, October 2010. URL: http://dx.doi.org/10.1073/pnas.1013309107, doi:10.1073/pnas.1013309107. This article has 40 citations.](https://doi.org/10.1073/pnas.1013309107)

[8. (Wihlborg2004ADP) Anna-Karin Wihlborg, Lingwei Wang, Oscar Östberg Braun, Atli Eyjolfsson, Ronny Gustafsson, Tomas Gudbjartsson, and David Erlinge. Adp receptor p2y 12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(10):1810–1815, October 2004. URL: http://dx.doi.org/10.1161/01.atv.0000142376.30582.ed, doi:10.1161/01.atv.0000142376.30582.ed. This article has 151 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1161/01.atv.0000142376.30582.ed)

[9. (von2017Structure) Ivar von Kügelgen. Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor, pages 123–138. Springer Singapore, 2017. URL: http://dx.doi.org/10.1007/5584_2017_98, doi:10.1007/5584_2017_98. This article has 24 citations.](https://doi.org/10.1007/5584_2017_98)

[10. (Zhang2014Agonistbound) Jin Zhang, Kaihua Zhang, Zhan-Guo Gao, Silvia Paoletta, Dandan Zhang, Gye Won Han, Tingting Li, Limin Ma, Wenru Zhang, Christa E. Müller, Huaiyu Yang, Hualiang Jiang, Vadim Cherezov, Vsevolod Katritch, Kenneth A. Jacobson, Raymond C. Stevens, Beili Wu, and Qiang Zhao. Agonist-bound structure of the human p2y12 receptor. Nature, 509(7498):119–122, April 2014. URL: http://dx.doi.org/10.1038/nature13288, doi:10.1038/nature13288. This article has 271 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature13288)

[11. (Cattaneo2015P2Y12) M. Cattaneo. P2y12 receptors: structure and function. Journal of Thrombosis and Haemostasis, 13:S10–S16, June 2015. URL: http://dx.doi.org/10.1111/jth.12952, doi:10.1111/jth.12952. This article has 114 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/jth.12952)

[12. (Mansour2020P2Y12) Alexandre Mansour, Christilla Bachelot-Loza, Nicolas Nesseler, Pascale Gaussem, and Isabelle Gouin-Thibault. P2y12 inhibition beyond thrombosis: effects on inflammation. International Journal of Molecular Sciences, 21(4):1391, February 2020. URL: http://dx.doi.org/10.3390/ijms21041391, doi:10.3390/ijms21041391. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21041391)

[13. (Entsie2023The) Philomena Entsie, Ying Kang, Emmanuel Boadi Amoafo, Torsten Schöneberg, and Elisabetta Liverani. The signaling pathway of the adp receptor p2y12 in the immune system: recent discoveries and new challenges. International Journal of Molecular Sciences, 24(7):6709, April 2023. URL: http://dx.doi.org/10.3390/ijms24076709, doi:10.3390/ijms24076709. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24076709)

[14. (Fontana2003P2Y) Pierre Fontana, Pascale Gaussem, Martine Aiach, Jean-Noël Fiessinger, Joseph Emmerich, and Jean-Luc Reny. P2y 12 h2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation, 108(24):2971–2973, December 2003. URL: http://dx.doi.org/10.1161/01.cir.0000106904.80795.35, doi:10.1161/01.cir.0000106904.80795.35. This article has 133 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/01.cir.0000106904.80795.35)

[15. (Gachet2012P2Y12) Christian Gachet. P2y12 receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signalling, 8(3):609–619, April 2012. URL: http://dx.doi.org/10.1007/s11302-012-9303-x, doi:10.1007/s11302-012-9303-x. This article has 108 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11302-012-9303-x)